| Home | E-Submission | Sitemap | Editorial Office |  
Korean J Urol Oncol > Volume 6(3); 2008 > Article
The Korean Journal of Urological Oncology 2008;6(3): 127-132.
국소진행성 전립선암에서 저선량 근접치료의 적용
박동수, 장웅기, 오종진, 지상현, 신현수
포천중문의과대학교 분당차병원 비뇨기과학교실, 1방사선종양학교실
Application of Low Dose Rate Brachytherapy in Locally Advanced Prostate Cancer
Dong Soo Park , Woong Ki Jang , Jong Jin Oh , Sang Hyun Jee , Hyun Soo Shin
Departments of Urology and 1Radiation Oncology, Bundang CHA Hospital, Pochon CHA University College of Medicine, Seongnam, Korea
Published online: December 1, 2008.
We have applied the low dose rate brachytherapy to locally advanced prostate cancer and evaluated the feasibility as a core treatment strategy in high- and very high-risk groups of prostate cancer patients.
Materials and Methods:
A total of 50 consecutive patients have been treated with brachytherapy for one year since April 2007. Patients were classified using four risk stratifications of low, intermediate, high, and very high. Fifteen out of 23 patients were in high-risk group (clinical T3a-T3b or Gleason score 8-10 or PSA >20ng/ml) and 8 patients were in very high-risk group (clinical T3c-T4 or any T, N1-3). Iodine-125 Implantations were performed by practicing a real-time ultrasound guided seed placement including prostatic capsular and seminal vesicular placement. Eight out of 15 high-risk patients and all of the very high-risk patients received booster 45Gy external beam radiation. All of the 22 patients were treated with short-term androgen deprivation therapy.
The median radiation doses delivered to 90% of the prostate (D90) in high-risk and very high-risk group were 197.5Gy (range: 142.5-357.5Gy) and 210Gy (range: 137.5-277.5Gy). Biochemical failure was not revealed in any case during follow up. All patients experienced no major complications.
We can expect outstanding local control in locally advanced prostate cancer by applying very high implant doses and modifying insertion field. Our technique of low dose rate brachytherapy would be feasible and tolerable in patients of high- and very high-risk groups. However, this strategy needs to have a long-term follow up data. (Korean J Urol Oncol 2008;6:127-132)
Key Words: Prostate; Cancer; Brachytherapy; Risk
Editorial Office
Department of Urology, Chung-Ang University Hospital
102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-1819   Fax: +82-2-6294-1406   E-mail: journal@kjuo.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Urological Oncology Society and The Korean Prostate Society. All rights reserved.                 developed in m2community
Close layer
prev next